Gotham Asset Management LLC Has $13.47 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Gotham Asset Management LLC reduced its stake in Vertex Pharmaceuticals by 7.8%, owning 27,777 shares valued at approximately $13.47 million after selling 2,334 shares in the 1st quarter.
• In a recent insider transaction, Director Bruce I. Sachs acquired 5,000 shares at $389.68 each, boosting his total holdings to 45,000 shares valued at $17.54 million.
• Vertex Pharmaceuticals reported $4.52 earnings per share in its latest quarterly earnings, surpassing analysts' estimates, with a revenue increase of 11.3% on a year-over-year basis.

Gotham Asset Management LLC trimmed its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 7.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,777 shares of the pharmaceutical company's stock after selling 2,334 shares during the quarter. Gotham Asset Management LLC's holdings in Vertex Pharmaceuticals were worth $13,467,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Activest Wealth Management purchased a new position in shares of Vertex Pharmaceuticals in the first quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd increased its stake in shares of Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 45 shares in the last quarter. Mascagni Wealth Management Inc. purchased a new stake in Vertex Pharmaceuticals in the 4th quarter worth $31,000. Mpwm Advisory Solutions LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $40,000. Finally, Minot DeBlois Advisors LLC bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at about $44,000. 90.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on VRTX shares. UBS Group set a $553.00 price objective on shares of Vertex Pharmaceuticals and gave the company a "buy" rating in a report on Tuesday, August 5th. JPMorgan Chase & Co. raised their price target on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the stock an "overweight" rating in a report on Monday, July 14th. Wells Fargo & Company upgraded shares of Vertex Pharmaceuticals from an "equal weight" rating to an "overweight" rating and set a $460.00 price target for the company in a research note on Wednesday, August 6th. Guggenheim dropped their price objective on shares of Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. Finally, Stifel Nicolaus lowered their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating on the stock in a research report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $497.10.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were bought at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the transaction, the director owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Stock Up 0.3%

Vertex Pharmaceuticals stock traded up $1.23 during trading hours on Tuesday, hitting $396.48. 946,736 shares of the company traded hands, compared to its average volume of 1,480,506. The firm's 50-day simple moving average is $426.38 and its two-hundred day simple moving average is $455.19. The firm has a market cap of $101.65 billion, a P/E ratio of 28.34 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same period in the previous year, the firm posted ($12.83) earnings per share. The firm's revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.